Chengcan Yang
Impact in
-
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
-
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Protein Degradation and Inhibitors 3
- Hedgehog Signaling Pathway Studies 2
- Epigenetics and DNA Methylation 2
- CRISPR and Genetic Engineering 2
- Ubiquitin and proteasome pathways 2
- Advanced biosensing and bioanalysis techniques 1
- Oncology 3
- PARP inhibition in cancer therapy 2
- Co-authors
- Liang Ouyang (9 shared papers)Jifa Zhang (8 shared papers)Guan Wang (5 shared papers)Minru Liao (2 shared papers)Yuxi Wang (3 shared papers)Juncheng Chen (6 shared papers)Pan Tang (5 shared papers)Yang Li (5 shared papers)
- Journals
- Journal of Medicinal Chemistry (6 papers)European Journal of Medicinal Chemistry (1 paper)Oral Diseases (1 paper)Acta Pharmaceutica Sinica B (1 paper)Drug Discovery Today (1 paper)
- Partner nations
- ChinaUnited StatesPoland
In The Last Decade
Chengcan Yang
14 papers receiving 367 citations
Peers
Comparison fields: 5 of 76
- Molecular Biology 263
- Cancer Research 48
- Hematology 31
- Oncology 74
- Physiology 11
Countries citing papers authored by Chengcan Yang
This map shows the geographic impact of Chengcan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengcan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengcan Yang more than expected).
Fields of papers citing papers by Chengcan Yang
This network shows the impact of papers produced by Chengcan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengcan Yang. The network helps show where Chengcan Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Chengcan Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 72 | |
| 2 | 2022 | 63 | |
| 3 | 2022 | 36 | |
| 4 | 2021 | 34 | |
| 5 | 2021 | 32 | |
| 6 | 2022 | 32 | |
| 7 | 2021 | 31 | |
| 8 | 2022 | 15 | |
| 9 | 2023 | 14 | |
| 10 | 2021 | 13 | |
| 11 | 2021 | 13 | |
| 12 | 2020 | 5 | |
| 13 | 2020 | 4 | |
| 14 | 2022 | 4 |
About Chengcan Yang
Chengcan Yang is a scholar working on Molecular Biology, Oncology, Epidemiology, Cancer Research and Infectious Diseases, having authored 14 papers that have together received 368 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (3 papers), Autophagy in Disease and Therapy (3 papers), Hedgehog Signaling Pathway Studies (2 papers), Epigenetics and DNA Methylation (2 papers), PARP inhibition in cancer therapy (2 papers), CRISPR and Genetic Engineering (2 papers), Ubiquitin and proteasome pathways (2 papers) and Advanced biosensing and bioanalysis techniques (1 paper). The work is most often cited by research in Molecular Biology (263 citations), Cancer Research (48 citations), Hematology (31 citations), Oncology (74 citations) and Physiology (11 citations). Chengcan Yang has collaborated with scholars based in China, United States and Poland. Frequent co-authors include Liang Ouyang, Jifa Zhang, Guan Wang, Minru Liao, Yuxi Wang, Juncheng Chen, Pan Tang, Yang Li, Yu‐Shang Yang and Bo Liu. Their work appears in journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Oral Diseases, Acta Pharmaceutica Sinica B and Drug Discovery Today.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.